Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

TriArm Therapeutics Completes $20 Million Series A Round for Cell Therapies

publication date: Jul 30, 2019

TriArm Therapeutics of Shanghai, Germany and Taiwan completed a $20 million Series A financing to develop next-gen cellular therapies. Founded in 2018, TriArm is developing a CD19 CAR-T product that has a two-to-three-day manufacturing process, which is much shorter than the current three-week process. The A round was led by Panacea Venture, the company's original backer. In December 2018, TriArm formed a $35 million JV, called Eden BioCell, with Boston's Ziopharm for China rights to third-gen CAR-T therapies targeting the CD19 antigen. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital